Application 761398

Type
BLA
Sponsor
FRESENIUS KABI USA LLC

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761398Conexxencedenosumab-bnht351(k) InterchangeableRx2026-07-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001BOMYNTRADENOSUMAB-BNHTINJECTION120MG/1.7ML (70 MG/ML)NoNo
002CONEXXENCEDENOSUMAB-BNHTINJECTION60MG/MLNoNo

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 ยท 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CONEXXENCEDENOSUMABFresenius Kabi USA, LLC39a0a789-778f-4695-b3a9-61643e6396cd2025-12-15Boxed warning, Warnings, Adverse reactionsExact identifier
application number: BLA761398
BOMYNTRADENOSUMABFresenius Kabi USA, LLC49d25732-e05d-47e4-98cb-67df04796d4b2025-03-31Warnings, Adverse reactionsExact identifier
application number: BLA761398

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
84322ORIG 2025-11-26
84320ORIG 2025-11-26
84319ORIG 2025-11-26
84001ORIG 2025-10-31
81745ORIG 2025-03-27
81725ORIG 2025-03-25